Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial.
Junqi Niu, Yanhang Gao, Guiqiang Wang, Zhijie Qin, Cuisong Wu, Zujiang Yu, Lichun Wang, Zhongjie Hu, Xing Li, Zong Zhang, Yue Chen, Lvfeng Yao, Jinhui Yang, Guang-Ming Li, Yida Yang, Xiaobo Lu, Ye Gu, Xiaofeng Wu, Xiaorong Mao, Zhongyin Zhou, Jia Shang, Bingliang Lin, Ji-Dong Jia, Fengmei Wang, Jiming Zhang, Hongyan Ma, Xinrui Wang, Cliff Y Yang, Daichang Yang
Gut 74(9) 1476-1485
摘要
摘要
BACKGROUND: Despite inadequate supply and potential contamination risk, human plasma has remained the only source for human serum albumin (pHSA) intravenous administration since the 1940s. OBJECTIVE: We sought to establish the safety and efficacy of OsrHSA, a recombinant HSA from bioengineered Oryza sativa (rice). DESIGN: In this multicentre, randomised, double-blind and positive-controlled study, patients with decompensated liver cirrhosis and serum albumin ≤30 g/L were recruited from 22 centres in China. The patients were randomly assigned to OsrHSA or pHSA (4:1) to once-daily intravenous injection (10 g or 20 g) until their serum albumin level reached 35 g/L, for a maximum of 2 weeks, with 2 weeks of follow-up. The primary outcome was the proportion of patients to reach a serum albumin level of 35 g/L (non-inferiority margin <-0.20). Outcomes were evaluated in patients who received the study drug and had at least one post-baseline serum albumin value (full analysis set, FAS). Safety was evaluated in all patients who received the study drug. RESULTS: Between 22 March 2021 and 2 June 2022, 220 patients received OsrHSA (n=175) or pHSA (n=45). 216 patients were included in the FAS (OsrHSA, n=171; pHSA, n=45). Primary outcome of OsrHSA (130/171, 76%) was non-inferior to pHSA (34/45, 75.6%) (difference=0.5%; lower limit of 97.5% CI=-0.119). There was no significant difference between all secondary outcomes of OsrHSA and pHSA. There were no drug-related serious adverse events. CONCLUSIONS: Rice-derived HSA is non-inferior to plasma-derived HSA in efficacy and safety. This finding should be confirmed in phase 3 trial. TRIAL REGISTRATION NUMBER: NCT04835480.
KM 提取结果
0 个 Figure · 0 个 KM 面板